keyword
MENU ▼
Read by QxMD icon Read
search

Aclidinium

keyword
https://www.readbyqxmd.com/read/27853383/uk-specific-cost-effectiveness-of-tiotropium-olodaterol-fixed-dose-combination-versus-other-lama-laba-combinations-in-patients-with-copd
#1
Abigail Tebboth, Andrew Ternouth, Nuria Gonzalez-Rojas
OBJECTIVE: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combinations in comparison with Spiolto(®) Respimat(®) (tiotropium + olodaterol fixed-dose combination [FDC]) for maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. METHODS: A previously published individual-level Markov model was adapted for the perspective of the UK health care system, in line with recommendations from the National Institute for Health and Care Excellence...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27825347/non-neuronal-cholinergic-system-contributes-to-corticosteroid-resistance-in-chronic-obstructive-pulmonary-disease-patients
#2
Javier Milara, Angela Cervera, Alfredo de Diego, Celia Sanz, Gustavo Juan, Amadeu Gavaldà, Montserrat Miralpeix, Esteban Morcillo, Julio Cortijo
BACKGROUND: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect...
November 8, 2016: Respiratory Research
https://www.readbyqxmd.com/read/27787709/muscarinic-receptor-antagonists
#3
Maria Gabriella Matera, Mario Cazzola
Parasympathetic activity is increased in patients with chronic obstructive pulmonary disease (COPD) and asthma and appears to be the major reversible component of airway obstruction. Therefore, treatment with muscarinic receptor antagonists is an effective bronchodilator therapy in COPD and also in asthmatic patients. In recent years, the accumulating evidence that the cholinergic system controls not only contraction by airway smooth muscle but also the functions of inflammatory cells and airway epithelial cells has suggested that muscarinic receptor antagonists could exert other effects that may be of clinical relevance when we must treat a patient suffering from COPD or asthma...
October 28, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27672337/cost-versus-utility-of-aclidinium-bromide-400-%C3%A2%C2%B5g-plus-formoterol-fumarate-dihydrate-12-%C3%A2%C2%B5g-compared-to-aclidinium-bromide-400-%C3%A2%C2%B5g-alone-in-the-management-of-moderate-to-severe-copd
#4
Mafalda Ramos, John Haughney, Nathaniel Henry, Leandro Lindner, Mark Lamotte
PURPOSE: Aclidinium-formoterol 400/12 µg is a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist in a fixed-dose combination used in the management of patients with COPD. This study aimed to assess the cost-effectiveness of aclidinium-formoterol 400/12 µg against the long-acting muscarinic antagonist aclidinium bromide 400 µg. MATERIALS AND METHODS: A five-health-state Markov transition model with monthly cycles was developed using MS Excel to simulate patients with moderate-to-severe COPD and their initial lung-function improvement following treatment with aclidinium-formoterol 400/12 µg or aclidinium 400 µg...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27621610/the-efficacy-of-aclidinium-formoterol-on-lung-function-and-symptoms-in-patients-with-copd-categorized-by-symptom-status-a-pooled-analysis
#5
Marc Miravitlles, Kenneth R Chapman, Ferran Chuecos, Anna Ribera, Esther Garcia Gil
BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of life. This pooled analysis of two Phase III studies assessed the impact of aclidinium/formoterol on patients with COPD categorized by symptom status. METHODS: Data were pooled from two 24-week, randomized, placebo-controlled studies of twice-daily aclidinium/formoterol 400/12 µg in moderate-to-severe COPD (ACLIFORM [NCT01462942] and AUGMENT [NCT01437397])...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27492833/efficacy-and-safety-of-aclidinium-formoterol-versus-salmeterol-fluticasone-a-phase-3-copd-study
#6
Claus Vogelmeier, Pier Luigi Paggiaro, Jordi Dorca, Pawel Sliwinski, Marcel Mallet, Anne-Marie Kirsten, Jutta Beier, Beatriz Seoane, Rosa Maria Segarra, Anne Leselbaum
The efficacy and safety of twice-daily aclidinium bromide/formoterol fumarate was compared with that of salmeterol/fluticasone propionate in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD).AFFIRM COPD (Aclidinium and Formoterol Findings in Respiratory Medicine COPD) was a 24-week, double-blind, double-dummy, active-controlled study. Patients were randomised (1:1) to aclidinium/formoterol 400/12 µg twice-daily via Genuair/Pressair or salmeterol/fluticasone 50/500 µg twice-daily via Accuhaler...
October 2016: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/27387608/symptoms-and-quality-of-life-in-patients-with-chronic-obstructive-pulmonary-disease-treated-with-aclidinium-in-a-real-life-setting
#7
Peter Lange, Nina Skavlan Godtfredsen, Beata Olejnicka, Bo-Anders Paradis, Dan Curiac, Sjur Humerfelt, Gunilla Telg, Helene Nordahl Christensen, Magnus Alexander Bitsch, Elisabeth Wreford Andersen, Leif Bjermer
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a progressive disease with symptoms that can have a major impact on patients' physical health. The aim of this study was to evaluate quality of life (QoL), symptom severity and dyspnoea in COPD patients treated with aclidinium up to 24 weeks. METHODS: In this prospective non-interventional multicentre study (198 centres in Sweden, Denmark, and Norway), COPD patients (age ≥40 years) who started treatment with aclidinium (initial therapy, change of treatment, or add-on therapy) could be included...
2016: European Clinical Respiratory Journal
https://www.readbyqxmd.com/read/27296819/long-term-safety-of-aclidinium-bromide-formoterol-fumarate-fixed-dose-combination-results-of-a-randomized-1-year-trial-in-patients-with-copd
#8
James F Donohue, Weily Soong, Xiao Wu, Pomy Shrestha, Alejhandra Lei
TRIAL DESIGN: This was a one-year, Phase III randomized, double-blind, parallel-group, active-control study investigating the long-term safety and tolerability of twice-daily aclidinium 400 μg/formoterol 12 μg versus formoterol 12 μg. METHODS: Eligible patients were male or female, current or ex-smokers (history of ≥10 pack-years) aged ≥40 years with a diagnosis of moderate to severe chronic obstructive pulmonary disease (COPD): post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio <70%, and post-bronchodilator FEV1≥30% and <80% predicted...
July 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27254952/-role-of-bronchodilators-in-therapy-for-copd-mechanisms-of-laba-and-lama-on-airway-smooth-muscle
#9
REVIEW
Hiroaki Kume
Long-acting β2-adrenergic receptor agonists (LABAs) and anticholinergics (LAMAs) are widely used clinically as therpy for COPD. Clinical reports have demonstrated that LABAs (salmeterol, formoterol, indacaterol, olodaterol, vilanterol) and LAMAs (tiotropium, glycopyrronium, umeclidinium, aclidinium) are useful to improving symptoms and lung function, and to reducing exacerbation and hospitarization. LABAs expect salmeterol are strong partial agonists, and LAMAs are non-specific antagonists. Ca2+ dynamics and Ca2+ sensitization contribute to relaxation of airway smooth muscle in these bronchodilators...
May 2016: Nihon Rinsho. Japanese Journal of Clinical Medicine
https://www.readbyqxmd.com/read/27215749/the-effect-of-aclidinium-bromide-on-daily-respiratory-symptoms-of-copd-measured-using-the-evaluating-respiratory-symptoms-in-copd-e-rs-copd-diary-pooled-analysis-of-two-6-month-phase-iii-studies
#10
Paul W Jones, Nancy K Leidy, Asha Hareendran, Rosa Lamarca, Ferran Chuecos, Esther Garcia Gil
BACKGROUND: Reducing the severity of respiratory symptoms is a key goal in the treatment of chronic obstructive pulmonary disease (COPD). We evaluated the effect of aclidinium bromide 400 μg twice daily (BID) on respiratory symptoms, assessed using the Evaluating Respiratory Symptoms in COPD (E-RS(™): COPD) scale (formerly EXACT-RS). METHODS: Data were pooled from the aclidinium 400 μg BID and placebo arms of two 24-week, double-blind, randomized Phase III studies evaluating aclidinium monotherapy (ATTAIN) or combination therapy (AUGMENT COPD I) in patients with moderate to severe airflow obstruction...
2016: Respiratory Research
https://www.readbyqxmd.com/read/27159613/effect-of-aclidinium-bromide-on-exacerbations-in-patients-with-moderate-to-severe-copd-a-pooled-analysis-of-five-phase-iii-randomized-placebo-controlled-studies
#11
Jadwiga A Wedzicha, Alvar Agusti, Gavin Donaldson, Ferran Chuecos, Rosa Lamarca, Esther Garcia Gil
We investigated the effect of the long-acting muscarinic antagonist aclidinium bromide on chronic obstructive pulmonary disease (COPD) exacerbations by pooling data from five randomized, placebo-controlled, parallel-group Phase III studies of 3-6 months' duration. Data were pooled from the aclidinium 400 μg twice-daily (BID) and placebo arms (N  =  2,521) and stratified by Global initiative for chronic Obstructive Lung Disease (GOLD) group (A, B, C and D). Results showed that fewer patients experienced ≥1 exacerbation with aclidinium (any severity: 12...
December 2016: COPD
https://www.readbyqxmd.com/read/27143870/dual-therapy-strategies-for-copd-the-scientific-rationale-for-lama-laba
#12
REVIEW
Joshua S Cohen, Matthew C Miles, James F Donohue, Jill A Ohar
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and health care expenditure worldwide. Relaxation of airway smooth muscle with inhaled bronchodilators is the cornerstone of treatment for stable COPD, with inhaled corticosteroids reserved for those with a history of exacerbations. Tiotropium has occupied center stage in COPD treatment for over 10 years and improves lung function, quality of life, exercise endurance, and reduces the risk of COPD exacerbation. Long-acting β2-agonists (LABAs) improve lung function, reduce dynamic hyperinflation, increase exercise tolerance, health-related quality of life, and reduce acute exacerbation of COPD...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27138024/pharmacokinetics-of-aclidinium-bromide-formoterol-fumarate-fixed-dose-combination-compared-with-individual-components-a-phase-1-open-label-single-dose-study
#13
Rainard Fuhr, Anne Leselbaum, Jordi Aubets
Inhaled, long-acting bronchodilators represent a cornerstone of maintenance treatment for chronic obstructive pulmonary disease (COPD). Aclidinium bromide/formoterol fumarate 400/12 μg fixed-dose combination (FDC) has recently been licensed for use in adults with COPD in the European Union. This phase 1, randomized, open-label, 3-way, complete crossover, single-dose study assessed the pharmacokinetics, safety, and tolerability of an FDC, aclidinium bromide 400 μg, and formoterol fumarate 12 μg, all administered via Genuair™ to 30 healthy subjects...
March 2016: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/27080033/downregulation-of-the-cough-reflex-by-aclidinium-and-tiotropium-in-awake-and-anesthetized-rabbits
#14
Donatella Mutolo, Elenia Cinelli, Ludovica Iovino, Tito Pantaleo, Fulvia Bongianni
Long-acting muscarinic receptor antagonists (LAMAs) have been reported to attenuate cough in preclinical and clinical studies. The present study was performed on rabbits to compare aclidinium and tiotropium efficacy in the downregulation of the cough reflex. This reflex was evoked by citric acid inhalation in unanesthetized animals and by both citric acid inhalation and mechanical stimulation of the tracheobronchial tree in anesthetized animals 90 min following the inhalation of each drug (nebulizer output always at 1 mL/min)...
April 11, 2016: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/26998725/aclidinium-bromide-inhalation-powder-for-the-long-term-maintenance-treatment-of-bronchospasm-associated-with-chronic-obstructive-pulmonary-disease-including-chronic-bronchitis-and-emphysema
#15
Maria Gabriella Matera, Alessandro Sanduzzi, Roberto Alfano, Mario Cazzola
Aclidinium is a twice-daily long-acting muscarinic receptor antagonist (LAMA) with an interesting pharmacological profile. Recent evidence indicates that this LAMA, in addition to causing a significant improvement in lung function and other important supportive outcomes, such as health related quality of life, dyspnea and nighttime/early morning symptoms in patients suffering from COPD, is also able to significantly reduce the rate of exacerbations of any severity, is extremely effective in controlling the COPD symptoms, is able to reduce lung hyperinflation, and has an excellent cardiovascular safety profile...
June 2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/26929634/new-combinations-in-the-treatment-of-copd-rationale-for-aclidinium-formoterol
#16
REVIEW
Cristoforo Incorvaia, Marcello Montagni, Elena Makri, Erminia Ridolo
The current guidelines on chronic obstructive pulmonary disease (COPD) recommend the prominent use of bronchodilators, including long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs), while inhaled corticosteroids are recommended only in patients with severe disease or frequent exacerbations. LABA-LAMA combinations are indicated when single bronchodilators are insufficient to control COPD. A number of LABA-LAMA combinations are available, based on twice-daily or once-daily administration according to the 12- or 24-hour duration of action, respectively...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/26924197/safety-considerations-with-dual-bronchodilator-therapy-in-copd-an-update
#17
REVIEW
Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta, Mario Cazzola
Combining a long-acting β2-agonist (LABA) with a long-acting anti-muscarinic agent (LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have major implications for the use of LABA/LAMA combinations in the treatment of chronic obstructive pulmonary disease (COPD). There are four different approved LAMA/LABA fixed-dose combinations (FDCs)-glycopyrronium/indacaterol, umeclidinium/vilanterol, tiotropium/olodaterol, and aclidinium/formoterol-and another, glycopyrronium/formoterol, that is still under clinical development...
June 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/26883661/efficacy-and-safety-of-aclidinium-formoterol-versus-tiotropium-in-copd-results-of-an-indirect-treatment-comparison
#18
REVIEW
Goran Medic, Leandro Lindner, Miriam van der Weijden, Andreas Karabis
INTRODUCTION: The objective of this study was to estimate the relative efficacy and safety of fixed-dose combination aclidinium/formoterol 400/12 μg twice daily compared to tiotropium 18 μg once daily in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). METHODS: A systematic literature review performed in March 2014, using a predefined search strategy in MEDLINE, EMBASE and Cochrane Library, identified 17 randomized placebo-controlled trials, (tiotropium n = 15; aclidinium/formoterol n = 2)...
March 2016: Advances in Therapy
https://www.readbyqxmd.com/read/26846588/efficacy-and-safety-of-an-aclidinium-bromide-treatment-for-12-weeks-or-longer-in-patients-with-moderate-to-severe-copd-a-meta-analysis
#19
Yong Zou, Jian Xiao, Dan Hui Yang, Jun Li, Qiong Chen
BACKGROUND: Bronchodilators are commonly used to manage patients with stable chronic obstructive pulmonary disease (COPD). This meta-analysis assessed the efficacy of aclidinium bromide with respect to clinical events, health-related quality of life and symptom scales, pulmonary function, and safety among patients with stable COPD. METHODS: A comprehensive search of MEDLINE, EMBASE, CINAHL and the Cochrane Library databases was undertaken to identify randomized controlled trials (RCTs) that compared aclidinium with placebo, treatment over at least 12 weeks...
August 2016: COPD
https://www.readbyqxmd.com/read/26792987/specific-role-of-combination-aclidinium-formoterol-in-the-treatment-of-chronic-obstructive-pulmonary-disease
#20
REVIEW
Maria Gabriella Matera, Alessandro Sanduzzi, Mario Cazzola
Co-administration of a long-acting β2-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated...
2016: International Journal of Chronic Obstructive Pulmonary Disease
keyword
keyword
52233
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"